Leukaemia, which may be acute or chronic, is a cancer that originates in blood-forming tissue such as the bone marrow, leading to the over-production of abnormal white blood cells. These abnormal cells accumulate more quickly in acute leukaemia, which is more aggressive than chronic leukaemia.
Lymphocytes and myeloid cells are the two main white blood cell types affected in leukaemia, leading to four leukaemia manifestations including acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML) and chronic lymphocytic leukaemia (CLL). Symptoms vary depending on subtype and can include weakness, increased rates of infection and general feeling of illness.
Diagnosis may involve blood testing, bone marrow biopsy, spinal tap and imaging tests (for example, CT, MRI and PET scans). The subsequent treatment will depend on the type of leukaemia and how far it has spread. Treatments may include radiation therapy, chemotherapy, biologic therapy, immunotherapy, targeted therapy and haematopoietic stem cell transplantation.
Related news and insights
TG Therapeutics, Inc. announced that the Company has voluntarily withdrawn the pending Biologics License Application (BLA)/supplemental New Drug Application (sNDA) for the combination of ublituximab and Ukoniq (umbralisib) (combination referred to as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Brukinsa demonstrates superior overall response rate versus ibrutinib in final response analysis of ALPINE trial in chronic lymphocytic leukemia. BeiGene, Ltd. announced results from the Phase III ALPINE trial showing BTK inhibitor Brukinsa (zanubrutinib) demonstrated superiority versus ibrutinib in overall response rate (ORR) as assessed by an Independent Review Committee (IRC) in adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
BeiGene announced that the FDA has accepted a supplemental new drug application (sNDA) for Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
This guideline covers the planning and management of end of life and palliative care in for infants, children and young people (aged 0-17 years) with life-limiting conditions. It aims to involve children, young people and their families...
The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations.
In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...